| Literature DB >> 31436967 |
Jong-Jin Kim1,2, Yong-An Lee1,3, Dongdong Su1, Jungyeol Lee4, Sung-Jin Park1, Beomsue Kim1, Jia Hui Jane Lee3,5, Xiao Liu2, Seong Soon Kim6, Myung Ae Bae6, Jun-Seok Lee7, Seong Cheol Hong7, Lu Wang1,8, Animesh Samanta1,9, Haw-Young Kwon2, So-Young Choi, Jun-Young Kim10, Young Hyun Yu11, Hyung-Ho Ha11, Zhenxun Wang3, Wai Leong Tam3,12,13, Bing Lim3,14, Nam-Young Kang1,4, Young-Tae Chang1,2.
Abstract
Tumor initiating cells (TIC) are resistant to conventional anticancer therapy and associated with metastasis and relapse in cancer. Although various TIC markers and their antibodies have been proposed, it is limited to the use of antibodies for in vivo imaging or treatment of TIC. In this study, we discovered heme oxygenase 2 (HMOX2) as a novel biomarker for TIC and developed a selective small molecule probe TiNIR (tumor initiating cell probe with near infrared). TiNIR detects and enriches the functionally active TIC in human lung tumors, and through the photoacoustic property, TiNIR also visualizes lung TIC in the patient-derived xenograft (PDX) model. Furthermore, we demonstrate that TiNIR inhibits tumor growth by blocking the function of HMOX2, resulting in significantly increased survival rates of the cancer model mice. The novel therapeutic target HMOX2 and its fluorescent ligand TiNIR will open a new path for the molecular level of lung TIC diagnosis and treatment.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31436967 DOI: 10.1021/jacs.9b06068
Source DB: PubMed Journal: J Am Chem Soc ISSN: 0002-7863 Impact factor: 15.419